Work

211-astatine containing radiotherapeutics for the treatment of cancer

Year: 2023

Type: article

Abstract: Described herein is an alpha-emitting radionuclide, 211At, which has been incorporated into a selective sigma-2 ligand moiety to provide cytotoxic capabilities to a chemical compound. As described herein, a compound of formula (I), wherein R1-R4, m, and n are defined herein, was prepared and utilized in in vitro and in vivo tumor targeting of alpha-emitting sigma-2 ligand in a breast cancer model. In one embodiment, the compound is 5-(211At)—N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2,3-dimethoxybenzamide.

Source: OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information)

Author: Pryma, Daniel A.; Lieberman, Brian P.; Makvandi, Mehran; Mach, Robert H.

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4288087983

FWCI:

Cites:

Cited by:

Related to: 10